Maximum quantity allowed is 999
Please select the quantity
CAS RN: 89778-27-8 | Product Number: T2832
Toremifene Citrate
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- (Z)-4-Chloro-1-(4-dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate
- (Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine Citrate
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
$125.00
|
17 | 0 | It can be shipped in about 2 weeks after ordering | |
| 5G |
$389.00
|
9 | 0 | It can be shipped in about 2 weeks after ordering |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | T2832 |
Purity / Analysis Method 
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__6H__2__8ClNO·C__6H__8O__7 = 598.09 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 89778-27-8 |
| Related CAS RN
|
89778-26-7 |
| Reaxys Registry Number | 8181005 |
| PubChem Substance ID | 160871014 |
| Merck Index (14) | 9550 |
| MDL Number | MFCD01729016 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 162 °C(dec.) |
| Solubility (soluble in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy and while nursing. P273 : Avoid release to the environment. P260 : Do not breathe dust. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
Transport Information:
| H.S.code* | 2921.49-000 |
Application
Biofilm research
Reference
- Repurposing Toremifene for Treatment of Oral Bacterial Infections
Application
Toremifene Citrate: A Selective Estrogen Receptor Modulator (SERM)
Toremifene citrate is a widely used nonsteroidal anti-estrogen agent for the treatment of hormone-dependent breast cancer. Toremifene is metabolized by cytochrome P450 (CYP450) enzymes into active metabolites N-desmethyltoremifene which has anti-estrogen activity as well. They act as an estrogen receptor antagonist in breast tissue. Tamoxifen is commonly referred to as a selective estrogen receptor modulator (SERM), since it behaves as an estrogen receptor agonist in other tissues. (The product is for research purpose only.)
References
- Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model
- Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
- Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus
- Pharmacokinetics of selective estrogen receptor modulators (a review)
- Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance (a review)
Application
Studies on Materials for Controlled Release of Toremifene Citrate
References
- Silica xerogel as an implantable carrier for controlled drug delivery-evaluation of drug distribution and tissue effects after implantation
- Silica xerogel carrier material for controlled release of toremifene citrate
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Enter TCI Product Number
Enter KISHIDA Product Number
4-5 alphanumeric characters before the hyphen
7 alphanumeric characters
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
• The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
• Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
• If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
• Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
The requested analytical chart is not available. Sorry for the inconvenience.